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Abstract
Background: Health-related quality of life (HRQoL) is an important outcome to assess the impact of cancer. This
article examines the psychometric properties of the European Portuguese self-report version of the Pediatric Quality
of Life Inventory™ Cancer Module (PedsQL™ 3.0 Cancer Module) in children and adolescents with cancer.
Methods: The participants, 332 children/adolescents diagnosed with cancer (8–18 years old), completed measures
to assess HRQoL (PedsQL™ 3.0 Cancer Module and DISABKIDS Chronic Generic Measure; DCGM-12) and anxiety
(Revised Children’s Manifest Anxiety Scale - second edition; RCMAS-2). A subsample (n = 52) completed the
PedsQL™ 3.0 Cancer Module a second time following one-week. The pediatric oncologists completed the Intensity of
Treatment Rating Scale 3.0 (ITR 3.0).
Results: For the whole sample, the PedsQL™ 3.0 Cancer Module demonstrated good item discrimination (rs = .30
to .54). The confirmatory factor analysis testing the presence of eight first-order factors loading significantly in a
second-order factor revealed an acceptable fit (CFI = .91; RMSEA = .05). The correlation of PedsQL™ 3.0 Cancer Module
with DCGM-12 (rs = .17 to .58), and with RCMAS-2 (rs = −.16 to–.51) attested convergent validity. This inventory
demonstrated minimally acceptable to very good internal consistency (αs = .65 to .87) and temporal stability
(ICCs = .61 to .81).
Conclusions: These findings demonstrate that the European Portuguese self-report version of the PedsQL™ 3.0
Cancer Module is a valid and reliable instrument for assessing HRQoL in pediatric cancer.
Keywords: European Portuguese version, PedsQL™ 3.0 Cancer Module, Health-related quality of life, Pediatric
cancer, Psychometric properties
Background
According to the World Health Organization, the global
incidence rate of childhood cancer is approximately
100–150 cases per million children and adolescents
under 15 years of age [1]. In Europe, namely in Portugal,
as well as in North America, leukemias are the most
common childhood cancers, followed by central nervous
system tumors and lymphomas [2].
Clinical advancements in the treatment of this condi-
tion have led to a relevant reduction in mortality rates in
the last 50 years. Currently, 70 to 80 % of pediatric can-
cer patients can be cured in developed countries [3] if
diagnosed and treated early [4]. This progress, however,
has been achieved with aggressive medical protocols that
have a significant impact on children and adolescents’
daily lives, which affect, among other aspects, their
health-related quality of life (HRQoL) [5]. As survivor-
ship rates have increased concerns regarding patients’
HRQoL have become key aspects in cancer care.
HRQoL is a component of the more global construct
of quality of life [1] and has been defined as the patient’s
perception of the impact of the disease and treatment in
several domains, such as physical, mental and social [6].
Although HRQoL is, by definition, self-referential, the
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assessment of HRQoL in children and adolescents has,
until recently, primarily relied on parents’ reports [e.g., 7].
However, recent studies highlight that child reports can-
not be substituted with the parent reports, with the excep-
tion of patients too young, too cognitively impaired, or
too ill or fatigued to complete a HRQoL assessment
instrument [8]. Hence, similar to North America, it is im-
portant to make available a reliable and valid assessment
instrument in Portugal to measure children and adoles-
cents’ self-reported HRQoL in pediatric cancer patients
across different statuses of treatment [9].
A recent systematic review [10] identified 13 instru-
ments for assessing quality of life, which were developed
for use with children with cancer and childhood cancer
survivors. Nonetheless, only two, the Pediatric Quality of
Life Inventory™ Cancer Module (PedsQL™ 3.0 Cancer
Module) and the Quality of Life for Children with Cancer
Scale, were appropriate taking into account the following
requirements: (1) self-reported measure; (2) appropriate
for any type of cancer; (3) appropriate for both on- and
off-treatment status; and (4) comprising versions for both
children and adolescents. Nevertheless, none of them had
yet been translated and validated for Portuguese. The op-
tion for the PedsQL™ 3.0 Cancer Module was based on
the fact that it was currently the most widely used meas-
ure of child health [11] and had more psychometric data
published compared with other pediatric quality of life in-
struments [10].
However, to our knowledge, no published studies
have examined the factorial structure of the PedsQL™
3.0 Cancer Module using confirmatory factor analysis
(CFA). While exploratory factor analysis (EFA) is de-
signed for situations where links between the observed
and latent variables are unknown or uncertain, CFA en-
ables a specific hypothesized structure to be tested [12].
Because the PedsQL™ 3.0 Cancer Module was devel-
oped based on a theoretically driven model [13], the
use of CFA is appropriate.
Regarding the convergent validity of the self-report
version, with minor exceptions, previous studies [14–17]
have identified significant positive associations between
the scores of the PedsQL™ 3.0 Cancer Module and the
PedsQL™ 4.0 Generic Core Scales [13].
In addition, previous studies examining the reliability
of the PedsQL™ 3.0 Cancer Module self-report version
have demonstrated adequate values of internal consistency
[16, 17] and temporal stability [14, 15] for the total score.
Regarding the subscales, some studies found values below
the established cut points for internal consistency [18] and
temporal stability [14, 15].
Despite the growing support for the validity and reli-
ability of the PedsQL™ 3.0 Cancer Module, to date,
there is no evidence for its factorial validity, via CFA. In
addition, the convergent validity and the test-retest
reliability across age groups [for two exceptions: 14, 15]
remain understudied.
The present research aimed at examining the psycho-
metric properties of the self-reported European Portuguese
version of the PedsQL™ 3.0 Cancer Module in children/ad-
olescents. The specific objectives were to: (1) conduct de-
scriptive and item analyses for the whole sample; (2a) test
the factorial validity via CFA for the whole sample; (2b)
evaluate convergent validity in two age groups (children
8–12 vs. adolescents 13–18); (3) assess the internal con-
sistency, and the test-retest reliability in two age groups
(children 8–12 vs. adolescents 13–18).
Methods
Participants
The sample was composed of 332 children/adolescents
(174 boys and 158 girls) aged 8 to 18 years old (M = 13.0;
SD = 3.2) who were diagnosed with leukemias (n = 131,
39.5 %), lymphomas (n = 83, 25.0 %), solid tumor – non
central nervous system (n = 86, 25.9 %), and central ner-
vous system tumors (n = 32, 9.6 %). The majority of chil-
dren/adolescents had not experienced a relapse (n = 287,
86.4 %). Most children/adolescents (n = 186, 56.0 %)
belonged to families with low socioeconomic status.
The participants were divided into two age groups: chil-
dren (n = 143) aged 8 to 12 years old (M = 9.8; SD = 1.6)
and adolescents (n = 189) aged 13 to 18 years old (M =
15.5; SD = 1.5). With regard to the main sociodemo-
graphic and clinical characteristics, the groups differed ac-
cording to sex. Compared with the group of adolescents,
the children’s group had a higher percentage of boys. The
groups did not differ in socioeconomic status, treatment
status, or intensity of treatment. The sociodemographic
and clinical data of the sample are shown in Table 1.
Procedure
The present study was approved by the Ethics Commit-
tees of three Portuguese public hospitals: the Portuguese
Institute of Oncology and São João Hospital, both lo-
cated in Porto, and the Pediatric Department, Centro
Hospitalar e Universitário de Coimbra in Coimbra. Be-
tween June 2012 and September 2013 all participants
who met inclusion criteria were invited to participate,
using a consecutive sampling approach. Inclusion cri-
teria consisted of having a cancer diagnosis for at least 3
months; aged 8–18 years; receiving treatment for pri-
mary diagnosed/relapsed cancer (on-treatment) or had
finished antineoplastic treatments for primary diagnosed/
relapsed cancer within the last 60 months (off-treatment).
The exclusion criteria consisted of comorbidity with other
chronic illness (e.g., diabetes); major developmental disor-
ders (e.g., down syndrome); or end-of-life care. Of the 335
participants approached to participate, nearly all (n = 332)
provided data (99.4 %). The two participants that declined
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participation indicated that they were too busy or not in-
terested. The study aims were explained to all participants,
and informed consents were obtained from all parents
and from participants aged 13 years or more; assent was
obtained from the younger children in accordance with
the Declaration of Helsinki. The protocol was adminis-
tered in a separate room in either the inpatient (n = 35,
10.5 %) or outpatient (n = 297, 89.5 %) setting in the pres-
ence of a trained undergraduate and a graduate research
assistant. The participants who were scheduled to revisit
the hospital within a 1-week period were invited to
complete the PedsQL™ 3.0 Cancer Module a second time.
Twenty-two children (M = 9.9; SD = 1.5) and thirty adoles-
cents (M = 15.1; SD = 1.5) on-treatment agreed to do so
and were included in the test-retest analyses.
Linguistic validation was conducted for the PedsQL™ 3.0
Cancer Module, following the PedsQL Linguistic Validation
Guidelines [19]. The original scale was translated independ-
ently by two bilingual translators whose native language was
Portuguese. The two translated versions were analyzed by a
research group composed of five members (two psycholo-
gists and three nurses), who agreed on a single reconciled
version. A third bilingual translator conducted back-
translation of this reconciled version. The comparison of the
back-translation with the original source version found no
inaccuracies in the translation. Then, a face-to-face inter-
view was conducted by a graduate research assistant that
inquired whether the participants, five children and five
adolescents with cancer who were Portuguese native
speakers, had any difficulty in understanding the scale’s
items; the patients’ interpretations of the items were also
examined. Because the participants did not report diffi-
culty in understanding the items or in using the response
scale, the reconciled version was adopted as the final
version.
Measures
HRQoL (Cancer-Specific)
The PedsQL™ 3.0 Cancer Module [13] is the most updated
version of the initial PedsQL™ 1.0 Cancer Module [20]. There
is a self-report version for children (age range 8–12 years)
and another one for adolescents (age range 13–18 years),
that differs only in the wording of the instructions (i.e.,
“child(ren)” vs. “teen(s)”). Both these versions are com-
posed of 27 items grouped into eight subscales: Pain and
Hurt (2 items), Nausea (5 items), Procedural Anxiety (3
items), Treatment Anxiety (3 items), Worry (3 items),
Cognitive Problems (5 items), Perceived Physical Appear-
ance (3 items), and Communication (3 items). The partici-
pants evaluated how frequently a specific problem occurred
in the past one month (e.g., “I worry about side effects from
medical treatments”) using a 5-point Likert scale ranging
from 0 (never) to 4 (almost always). For more detail about
the Portuguese and English originals versions of the
PesdQL™3.0 Cancer Module, see Additional file 1. Accord-
ing to the original authors’ recommendations, the items
Table 1 Sociodemographic and Clinical Characteristics of the Sample
Whole sample Children Adolescents
N = 332 n = 143 n = 189
n % n % n % χ 2 Group differences
Sociodemographic
Sex χ2(1) = 4.50; p = .034; Cramér’s V = .12
Male 174 52.4 85 59.4 89 47.1
Female 158 47.6 58 40.6 100 52.9
Socioeconomic status χ2(2) = 2.98; p = .226; Cramér’s V = .10
Low 186 56.0 75 52.4 111 58.7
Medium 111 33.4 55 38.5 56 29.6
High 35 10.5 13 9.1 22 11.6
Clinical
Treatment status χ2(1) = 0.85; p = .357; Cramér’s V = .06
On-treatment 161 48.5 74 51.7 87 46.0
Off-treatment 171 51.5 69 48.3 102 54.0
Intensity of treatment χ2(3) = 4.59; p = .205; Cramér’s V = .12
Level 1: Least intensive 12 3.6 2 1.4 10 5.3
Level 2: Moderately intensive 112 33.7 53 37.1 59 31.2
Level 3: Very intensive 153 46.1 63 44.1 90 47.6
Level 4: Most intensive 55 16.6 25 17.5 30 15.9
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were reverse-scored and linearly transformed to fit a 0–100
scale with higher scores indicating better HRQoL. Subscales
and total scores were computed by taking the average of
the item scores.
HRQoL (Chronic health conditions)
The Portuguese version of the short-form of the
DISABKIDS Chronic Generic Measure [DCGM-12, 21]
was used to assess HRQoL. This instrument assesses the
HRQoL of children/adolescents aged 8–16 years old with
chronic health conditions. According to recent recom-
mendations [22], the final two items that concern medica-
tion were not included. The participants answered items
(e.g., “Does your condition get you down?”, “Is your life
ruled by your condition?”) on a 5-point Likert scale ran-
ging from 1 (never) to 5 (always). After reverse-scoring six
items, an overall score was obtained by averaging the sum
of all items, with higher scores indicating better HRQoL.
Cronbach’s alpha for the short-form was r = .84 [22]. For
our sample, Cronbach’s alpha ranged from .78 (children)
to .85 (adolescents).
Anxiety
Anxiety was assessed using the Portuguese version of the
Revised Children’s Manifest Anxiety Scale - Second Edi-
tion (RCMAS-2). The RCMAS-2 is a self-report instru-
ment designed to measure anxiety in children/adolescents
between 6 and 19 years old [23]. The participants an-
swered 10 items in short-form (e.g., “I often worry about
something bad happening to me”, “I have too many head-
aches”) using a dichotomous response format. Higher
scores indicate more anxiety. As reported in the technical
manual, a test-retest reliability of the short-form over one-
week was .54 and Cronbach’s alpha was .82 [23]. The
Kuder-Richardson coefficient (KR-20) in the present sam-
ple was .68 for children and .62 for adolescents.
Intensity of treatment
The Portuguese version of the Intensity of Treatment Rat-
ing Scale 3.0 [ITR-3.0; 24] was used to assess the intensity
of treatment. Fourteen pediatric oncologists used data
from the medical records, blind to patient identity, to clas-
sify each child’s treatment into 1 of 4-levels of intensity,
from 1 (least intensive treatment) to 4 (most intensive
treatment), based on the diagnosis, the phase of illness
(primary diagnosis or relapse), the stage/risk level for the
patient, and the treatment modalities. Inter-rater reliability
for a subset of this sample (n = 59) was k = .97 [25].
Socioeconomic status
The socioeconomic status of each family was classified in
three levels (low, medium and high) using data from both
parents’ job and educational level, according to an accepted
classification system for the Portuguese context [26].
Data analysis
Data analysis was conducted using Statistical Package for
the Social Sciences (SPSS) and Analysis of Moment Struc-
tures (AMOS), versions 20.0 (IBM, SPSS Inc., Chicago,
IL). Chi-square analyses were conducted to compare the
two age groups regarding sociodemographic and clinical
characteristics. Acceptance of the PedsQL™ 3.0 Cancer
Module was assessed, by referring to the percentage of
missing values per item. For descriptive and item analyses,
the means, standard deviations, medians, interquartile
ranges of the total score, subscales and items were com-
puted. Floor and ceiling effects, skewness and kurtosis in
the distributions of scores were also calculated. Floor or
ceiling effects were considered to be present if more than
15 % of respondents achieved the lowest or highest pos-
sible score, respectively [27, 28]. Considering a sample size
of more than 300 participants (N = 332), absolute skew-
ness values of over 2 or absolute kurtosis over 7 were used
as reference values for determining substantial non-
normality [29, 30]. In addition, corrected item to total
scale correlations were calculated; values r > .20 and ≥ .30
indicated moderate discrimination and good discrimin-
ation, respectively [31].
A CFA using robust Maximum likelihood (ML) was
conducted to test whether the empirical data confirmed
the factorial structure of the PedsQL™ 3.0 Cancer Mod-
ule proposed in the theoretical model advanced by Varni
et al. [13], which included a general second-order factor
that informed eight specific subscales. A threshold of .40
was used for factor loadings [32]. To assess for model fit,
evaluation of the chi-square statistic is recommended.
However, because chi-square is sensitive to sample size
[33], other goodness of fit indices were considered, includ-
ing the comparative fit index (CFI) and the root mean
square error of approximation (RMSEA) [12]. Values
equal or above .90, and .95 for the CFI are considered ac-
ceptable and very good fit, respectively [34]. For RMSEA,
a value lower than .01 indicates a great fit, values from .02
to .05 indicate a good fit and values up to .08 indicate an
acceptable fit [34].
The convergent validity was assessed through Pearson
correlation coefficients between the PedsQL™ 3.0 Cancer
Module and the DCGM-12, an additional measure of
HRQoL, and between the PedsQL™ 3.0 Cancer Module
and the RCMAS-2, a measure of a different construct,
that is, anxiety, which is theoretically related with
HRQoL [35, 36].
The internal consistency was measured with Cronbach’s
alpha coefficients [37] values were considered to be
unacceptable (< .60), undesirable (.60–.65), minimally ac-
ceptable (.65–.70), respectable (.70–.80), and very good
(.80–.90), according to DeVellis [35]. Test-retest reliability
was assessed with intraclass correlation coefficient (ICC);
values ≤ .40 were considered to be weak; values .41–.60
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were considered to be moderate; values .61–.80 were con-
sidered to be good and values ≥ .81were considered to be
excellent [38].
The effect sizes [39] are reported for comparison and
association analyses (small: r ≥ .10, Cramer’s V ≥ .01;
medium: r ≥ .30, Cramer’s V ≥ .03; large: r ≥ .50, Cramer’s
V ≥ .05).
Results
Descriptive and item analyses
The percentage of missing items was 0 %. The means,
standard deviations, medians, interquartile ranges, floor
and ceiling effects, skewness, kurtosis, and corrected
item to total scale correlations for the whole sample are
presented in Table 2. There were no floor effects for the
Table 2 Descriptive and Item Analyses of the PedsQL™ 3.0 Cancer Module (N = 332)
Total Score / Subscales / Items Mean SD Median IQR Floor, % Ceiling, % Skewness Kurtosis Corrected item-total correlations
Total Score 75.1 13.6 75.9 18.3 0.0 0.6 −0.45 −0.17 —
Pain and Hurt 81.0 21.8 87.5 37.5 0.6 42.8 −1.10 0.65 —
PH1 78.4 25.5 100.0 50.0 0.9 50.3 −0.86 −0.32 .44
PH2 83.7 23.3 100.0 25.0 1.8 59.3 −1.42 1.64 .40
Nausea 74.1 25.0 80.0 40.0 0.6 24.1 −0.81 −0.32 —
N3 70.5 34.6 100.0 50.0 9.3 50.3 −0.75 −0.79 .44
N4 72.8 32.2 87.5 50.0 7.2 50.0 −0.85 −0.43 .43
N5 81.9 28.0 100.0 44.0 3.9 64.5 −1.41 1.01 .46
N6 78.8 28.5 100.0 50.0 3.9 56.3 −1.16 0.38 .49
N7 66.4 32.1 75.0 50.0 7.2 38.3 −0.48 −0.87 .51
Procedural Anxiety 76.9 25.2 83.3 41.7 1.2 31.3 −1.09 0.36 —
PA8 69.1 31.1 75.0 50.0 8.1 36.4 −0.80 −0.31 .39
PA9 84.9 25.7 100.0 25.0 2.7 67.8 −1.69 2.04 .40
PA10 76.7 30.6 100.0 50.0 6.3 53.6 −1.16 0.29 .36
Treatment Anxiety 89.6 17.2 100.0 16.7 0.0 61.1 −1.81 2.69 —
TA11 90.7 19.7 100.0 0.0 1.2 76.8 −2.45 6.14 .39
TA12 91.3 17.6 100.0 0.0 0.0 76.8 −1.97 2.95 .51
TA13 86.8 23.3 100.0 25.0 2.1 69.3 −1.86 3.03 .51
Worry 55.6 28.4 58.3 50.0 3.0 10.2 −0.11 −0.99 —
W14 66.6 31.1 75.0 50.0 6.3 35.8 −0.49 −0.80 .54
W15 50.2 36.9 50.0 75.0 21.7 26.2 0.07 −1.33 .41
W16 49.9 34.8 50.0 50.0 18.4 21.7 0.08 −1.19 .48
Cognitive Problems 72.3 18.8 70.0 30.0 0.0 10.8 −0.43 −0.18 —
CP17 72.8 27.4 75.0 50.0 4.2 39.2 −0.79 0.03 .50
CP18 63.6 32.6 75.0 50.0 9.6 32.8 −0.45 −0.85 .32
CP19 74.5 27.0 75.0 50.0 4.5 41.0 −0.95 0.44 .39
CP20 72.1 27.6 75.0 50.0 3.9 38.0 −0.74 −0.15 .37
CP21 78.5 24.1 75.0 50.0 1.2 46.4 −0.89 0.11 .39
Perceived Physical Appearance 77.7 23.4 83.3 33.3 0.6 33.1 −0.97 0.20 —
PPA22 79.7 26.5 100.0 50.0 2.7 55.4 −1.11 0.43 .36
PPA23 77.5 33.8 100.0 44.0 9.6 60.8 −1.29 0.26 .30
PPA24 76.0 30.7 100.0 50.0 5.7 52.7 −1.07 0.02 .40
Communication 78.6 21.0 83.3 33.3 0.6 30.1 −0.97 0.56 —
C25 80.9 24.7 100.0 25.0 1.8 53.6 −1.20 0.81 .37
C26 80.7 24.5 100.0 25.0 1.8 52.7 −1.19 0.83 .42
C27 74.2 30.2 75.0 50.0 5.4 47.0 −0.95 −0.11 .31
Note. SD standard deviation; IQR interquartile range
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total score, subscales, and items, except for two items of
the Worry subscale (W15, W16). There were ceiling ef-
fects for all items, six subscales (Pain and Hurt, Nausea,
Procedural Anxiety, Treatment Anxiety, Perceived Phys-
ical Appearance, Communication) but not for the total
score. The skewness statistic was −0.45 for the total
score and ranged from −1.81 to −0.11 for the subscales
and between −2.45 and 0.08 for the items. The kurtosis
statistic was −0.17 for the total score and ranged from
−0.99 to 2.69 for the subscales and between 1.33 and
6.14 for the items. Except for one item of the Treatment
Anxiety subscale (TA11), skewness and kurtosis values
of all items, all subscales and total score were below the
thresholds of 2 and 7, respectively suggested normality
was not violated. The item-total correlation coefficients
(rs = .30 to .54) suggested good discrimination of the
items.
Validity
Factorial validity
Results are provided in Fig. 1. A second-order CFA, which
comprised eight first-order factors and one second-order
factor, demonstrated acceptable fit to the data (χ2316 =
590.80; p < .001; CFI = .91; RMSEA = .05, 90 % CI .05, .06).
All standardized items loaded significantly in their re-
spective factors, with the factor loadings ranging from .47
to .88. Similarly, all eight first-order factors loaded signifi-
cantly in the second-order factor, with the factor loadings
ranging from .42 to .69.
Convergent validity
As shown in Table 3, the PedsQL™ 3.0 Cancer Module
was significantly and positively correlated with DCGM-
12 and negatively correlated with the RCMAS-2, with
the exception of the children’s reports of Nausea and
Procedural Anxiety, which did not reach significance.
For the whole sample and both age groups, most corre-
lations were medium to large.
Reliability
As indicated in Table 4, for the whole sample and both
age groups, the total scale had very good internal
consistency. For the subscales, the scores were more het-
erogeneous, with values that ranged from minimally
HRQoL
.58
.47**
.42**
.66**
.66**
.69**
.61**
.55**
PH1
PH2
Pain and Hurt
Nausea
.74**
.81
.54**
.86**
.80**
N3
N4
N5
N6
N7
Procedural 
Anxiety
PA8
PA9
PA10
Treatment 
Anxiety
TA11
TA12
TA13
.75**
Worry
W14
W16
W15
.71**
CP17
CP18
CP19
CP20
CP21
Cognitive
Problems
.59**
.57**
.68**
Perceived
Physical
Appearance
Communication
PPA23
PPA24
PPA22
C25
C27
C26
.62
.70**
.83**
.88**
.74
.75**
.72**
.75
.54
.47**
.75
.74**
.81
.88**
.49**
.56**
.69
Free path
Fixed path
Fig. 1 Fit indexes for the model: χ2316 = 590.80; p < .001; CFI = .91; RMSEA = .05. Values shown in the figure represent completely standardized
regression weights of the factor loadings. **p < .01
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acceptable to very good internal consistency, with the
exception of the children’s reports of Pain and Hurt,
Cognitive Problems, and Perceived Physical Appearance.
With regard to the test-retest ICC values for the total
scale and subscales, these were good to excellent, with
the exception of Pain and Hurt and Cognitive Problems
for children, who presented moderate values (Table 4).
Discussion
The aim of this study was to assess the psychometric
properties of the European Portuguese version of the
PedsQL™ 3.0 Cancer Module for children and adoles-
cents. The findings supported the factorial structure and
the convergent validity. Overall, results also suggested
good internal consistency and temporal stability.
The absence of missing data suggested that children
and adolescents were willing and able to provide data.
Similar to other versions [e.g. 14–16, 20] there was a
tendency for ceiling effect for the subscales and items.
This tendency has been reported in other studies concern-
ing the measurement of HRQoL for children/adolescents
with cancer [40]. The inclusion of children/adolescents
that were off-treatment may have potentially accentuated
the ceiling effects [20]. This study increases current know-
ledge by showing that total scores and all subscales of the
PedsQL 3.0 Cancer Module were normally distributed, a
trend that has been reported in other studies [14, 15]. In
addition, similar to the Brazilian version [17], item-total
correlations demonstrated good item discrimination.
Although the PedsQL™ 3.0 Cancer Module has been
translated into 25 languages and some psychometric prop-
erties of these versions have been reported [e.g., 14, 15, 16],
to our knowledge, this is the first study to analyze the
factorial structure of this instrument via CFA. In ac-
cordance with the factorial structure proposed by the
original authors [13], the CFA indicated a second-order
Table 3 Convergent Validity of the PedsQL™ 3.0 Cancer Module
DCGM-12a RCMAS-2a
Whole sample Children Adolesc Whole sample Children Adolesc
(N = 332) (n = 143) (n = 189) (N = 332) (n = 143) (n = 189)
Total score .58** .61** .56** -.51** -.46** -.56**
Pain and Hurt .46** .34** .55** -.33** -.26** -.40**
Nausea .43** .42** .44** -.16** -.14 -.18**
Procedural Anxiety .17** .21** .15* -.17** -.09 -.26**
Treatment Anxiety .29** .35** .26** -.29** -.26** -.33**
Worry .34** .37** .34** -.32** -.36** -.33**
Cognitive Problems .39** .43** .36** -.44** -.40** -.48**
Perceived Physical Appearance .35** .33** .37** -.45** -.40** -.52**
Communication .32** .37** .28** -.37** -.31** -.43**
Note. Adolesc = adolescents
**p ≤ .01. *p < .05
aPearson correlations coefficients
Table 4 Internal Consistency and Test-retest Reliability of the PedsQL™ 3.0 Cancer Module
Internal consistencya Test-retest reliability (one-weak)b
Whole sample Children Adolesc Whole sample Children Adolesc
(N = 332) (n = 143) (n = 189) (N = 52) (n = 22) (n = 30)
Total score .87 .83 .89 .79** .70** .83**
Pain and Hurt .75 .58 .85 .61** .54** .63**
Nausea .86 .79 .90 .78** .78** .78**
Procedural Anxiety .82 .78 .87 .81** .76** .86**
Treatment Anxiety .80 .68 .87 .72** .89** .63**
Worry .77 .69 .81 .76** .68** .79**
Cognitive Problems .70 .61 .77 .77** .48** .87**
Perceived Physical Appearance .65 .49 .75 .81** .85** .78**
Communication .70 .69 .70 .74** .74** .75**
Note. Adolesc = adolescents
**p ≤ .01
aCronbach’s alpha; bIntraclass correlation coefficients
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factorial model and determined that the eight first-
order factors are structurally related and consistent in-
dicators of a higher level construct, that is, the HRQoL.
The correlations between the PedsQL™ 3.0 Cancer
Module and the DCGM-12, and the RCMAS-2 scores
attested the convergent validity. The medium to large
correlations between the two instruments, that measure
the HRQoL, were similar compared to the original ver-
sion [13], the Japanese version [15] and the Chinese ver-
sion [14] that compared the PedsQL™ 3.0 Cancer
Module and the PedsQL™ 4.0 Generic Core Scales. The
unique contributions of our study, compared with
previous research with the PedsQL™ 3.0 Cancer Mod-
ule [13–17], are that the data are presented separately for
each age group and that the other scale that assessed the
HRQoL (DCGM-12) was not derived from the same the-
oretical framework. In addition, the majority of the corre-
lations between the PedsQL™ 3.0 Cancer Module and the
RCMAS-2 scores were also medium to large, with the ex-
ception of the children’s reports of Nausea and Procedural
Anxiety. However, the items of the RCMAS-2 are more
oriented for physiological anxiety, worry, and social anx-
iety [23] and not for the physical side effects of cancer
treatment (e.g., nausea, dysgeusia) or for the anxiety re-
lated to procedures (e.g., injections, blood tests, intraven-
ous therapy).
With regard to reliability, PedsQL™ 3.0 Cancer Module
exceeded the minimally acceptable internal consistency
cut-point, with the exception of the Pain and Hurt, Cogni-
tive Problems, and Perceived Physical Appearance sub-
scales in the self-reports of children. Similar to these
findings, others studies have also demonstrated poor in-
ternal consistency for one or all aforementioned subscales
[13, 17]. The low reliability of these subscales identified
across countries may be related to their small number of
items [41] and also to children’s learning difficulties, which
may mirror the cognitive and neuropsychological effects
of the treatment and the high rate of absenteeism [42]. Al-
though, in Portugal, the education of youth with cancer is
protected by Law (No. 71/2009 of August 6th) [43] with
school support being available upon request at home and
at the hospital, the treatment for pediatric cancer can
often interrupt regular school attendance, that might be
more critical for the children's group.
Finally, total score and all subscales demonstrated
good to excellent test-retest reliability, with the excep-
tion of two subscales for children. Similar to Lau et al.
[14], one of the only two studies presenting the test-
retest reliability for this age group, the subscales Pain
and Hurt and Cognitive Problems (for children) pre-
sented moderate test-retest reliability values. However,
the children/adolescents who participated in the test-
retest were undergoing treatment at the time of the study.
Thus, the low values in the aforementioned subscales may
reflect changes over the previous week (e.g., treatment
side effects, outpatient or inpatient treatment, interrupt
homebound services) or impact due to a specific situ-
ation (e.g., blood test, lumbar punctures) [44]. With few
exceptions, however, the overall results suggest that the
Portuguese version of the PedsQL™ 3.0 Cancer Module
is stable over time.
The strengths of the PedsQL™ 3.0 Cancer Module include
the sound theoretical background, the inclusion of the child-
centered features, that is, important domains of a child’s life,
which enables the child to assess his/her own HRQoL taking
into account his/her developmental stage [45] according to
the guidelines in this field [46, for a review]. A strength of
this specific study is its large sample size, which allowed
for analyzing the convergent validity and reliability of this
measure separately for children and adolescents. Add-
itionally, this was the first study to conduct the factorial
validity of the PedsQL™ 3.0 Cancer Module via CFA, pro-
viding empirical support for the original model proposed
by the original authors of this scale.
The current study also presents potential limitations. First,
the sample collection was conducted in three of the four-
oncology centers in Portugal. Although it is unlikely that re-
gional differences may influence how children/adolescents
perceive the impact of cancer on their own HRQoL, general-
izations should be made with caution. Second, we did not
control for the treatments and their side effects, and school
support over the two assessment moments. Third, an ana-
lysis of the parents’ proxy-reports was not conducted. Future
research should inspect the psychometric properties of par-
ents’ proxy-reports and the agreement between the parents’
proxy-reports and the children/adolescents’ self-reports.
Moreover, future studies with a larger sample should analyze
whether the factorial structure remains valid across groups
of children and adolescents and across on- and off-treatment
status.
Conclusions
This approach enlarged the potential use of the PedsQL™
3.0 Cancer Module in future research by demonstrating
the validity of assessing both a general HRQoL factor and
the eight specific subscales provided by each subscale. The
study established that the European Portuguese version of
the PedsQL™3.0 Cancer Module for child and adolescent
self-report was a reliable and valid measurement instru-
ment to assess children/adolescent reports of HRQoL,
thereby expanding the potential for cross-cultural applica-
tions of the PedsQL™ 3.0 Cancer Module.
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